Tmunity is now part of Kite, a Gilead Company. Kite’s singular focus is cell therapy to treat and potentially cure cancer. Follow @KitePharma for updates.
Tune in at 1:30 PM EST as Tmunity CEO and President @OzAzamTmunity1 takes the stage to discuss next-gen T cell immunotherapies at #Cowen and Company’s 40th Annual Health Care Conference. #tmunitytx Listen here: wsw.com/webcast/cowen5…
Tmunity and CEO @OzAzamTmunity1 are thrilled to be in Boston to attend #Cowen and Company’s 40th Annual Health Care Conference. We’re looking forward to presenting the latest from our research efforts and connecting with investors. #tmunitytx
We’re honored to announce Tmunity President and CEO Dr. Oz Azam has been awarded @LifeSciencesPA’s Frank Baldino Bioscience CEO of the Year Award. His leadership at Tmunity and collaborations with @PennMedicine have been central to our success. #tmunitytx
We are pleased to announce Usman "Oz" Azam, MD, President and CEO, Tmunity Therapeutics Incorporated, has been selected as the recipient of the Frank Baldino Bioscience CEO of the Year Award! Congratulate him at the 2020 Annual Dinner on March 19! …-sciences-pennsylvania.ticketleap.com/2020-annual-di…
Tmunity celebrates International Day of Women and Girls in Science and the incredible contributions they have made to our world. #WomenInScience#WomenInSTEM#tmunitytx
Happy to announce that the first trial conducted under approval by the FDA to test multiplex CRISPR genome editing was published online in Science
sciencemag.org/news/2020/02/c…#CRISPR
CAR T therapy is one of our most powerful new cancer tools—maybe even a cure. With vein-to-vein logistics—removing cells, engineering them, and putting them back in your body—it's not just medicine. It's a whole new paradigm.
New pod: bit.ly/2vUuv3X
In an update to a first-in-U.S. #CRISPR trial, @PennCancer researchers show CRISPR-edited immune cells can survive and thrive after they’re infused into cancer patients. With @ParkerICI & @TmunityTX. Via @ScienceMagazine.